This was confirmed by the pediatric PAILOT (pediatric Crohn’s disease adalimumab level-based optimization treatment) study regarding ADA in CD and 1-year steroid-free clinical remission, as well as more composite outcomes (steroid-free clinical remission + normal CRP + normal FC (fecal calprotectin)) [76], and became further validated when applied for a longer time period, far from one year. This evidence concerns the gene CRP and Crohn disease.